Braidwell LP Sells 7,493,366 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Braidwell LP lessened its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 90.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 801,584 shares of the biopharmaceutical company's stock after selling 7,493,366 shares during the period. Braidwell LP owned 0.33% of Lexicon Pharmaceuticals worth $1,258,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. CVI Holdings LLC bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter worth approximately $34,000. Principal Financial Group Inc. grew its stake in shares of Lexicon Pharmaceuticals by 116.1% in the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 12,225 shares during the last quarter. Great Point Partners LLC bought a new stake in shares of Lexicon Pharmaceuticals in the second quarter worth $50,000. BNP Paribas Financial Markets increased its holdings in Lexicon Pharmaceuticals by 71.2% in the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 13,246 shares during the period. Finally, SG Americas Securities LLC raised its position in Lexicon Pharmaceuticals by 107.6% during the 3rd quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company's stock worth $72,000 after purchasing an additional 23,893 shares during the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Price Performance

Lexicon Pharmaceuticals stock remained flat at $0.80 during trading hours on Friday. The company's stock had a trading volume of 1,021,476 shares, compared to its average volume of 3,494,734. The stock's fifty day moving average price is $1.45 and its 200 day moving average price is $1.67. Lexicon Pharmaceuticals, Inc. has a 52-week low of $0.73 and a 52-week high of $3.73. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The firm has a market cap of $196.99 million, a price-to-earnings ratio of -1.07 and a beta of 1.24.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The company had revenue of $1.75 million for the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same period last year, the business earned ($0.21) EPS. Analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on LXRX shares. Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 22nd. HC Wainwright reiterated a "buy" rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. Finally, Leerink Partners set a $6.00 target price on shares of Lexicon Pharmaceuticals and gave the company an "outperform" rating in a research report on Friday, October 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Lexicon Pharmaceuticals has an average rating of "Hold" and an average price target of $6.00.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.